Heghine Khachatryan on the Lifeline of Blood: Why Every Donor is a Hero Behind the Science
Heghine Khachatryan, Editor-in-Chief of Hemostasis Today, Head of Hemophilia and Thrombosis Center at Yeolyan Hematology and Oncology Center, posted on LinkedIn:
“Blood transfusion saves lives – but only if there is a donor behind every unit of blood.
Every day, patients with cancer, blood diseases, trauma, massive bleeding, complicated pregnancies and major surgeries depend on safe blood transfusions. For them, donated blood is not just a product – it is a lifeline.
Modern transfusion medicine is highly regulated and evidence-based. Each unit of blood passes through strict testing, separation into components, and careful matching to the recipient. Behind every successful transfusion stands an invisible team: the voluntary donor, the laboratory specialists, the nurses and physicians who ensure that the right product reaches the right patient at the right time.
Yet in many hospitals we still experience critical shortages. This means postponed surgeries, limited treatment options, and sometimes the difference between life and death. Voluntary, regular, non-remunerated blood donation is the most sustainable way to guarantee safe blood for all who need it.
If you are healthy and eligible to donate, your contribution can:
• support patients with leukemia, lymphoma and aplastic anemia
• help women with severe obstetric bleeding
• stabilise patients after accidents and major surgery
• give children with hereditary blood disorders a chance to live full lives
Becoming a blood donor is one of the simplest and most powerful acts of solidarity.
It costs you around 20–30 minutes of your day, but it may add years to someone else’s life.
If you would like to support patients and our work in transfusion medicine, consider becoming a regular blood donor and invite your colleagues and friends to join you. Together we can build a culture where giving blood is a normal part of caring for our community.”
Get insights from Hemostasis Today.
-
Mar 16, 2026, 19:16Maha Othman: Delighted to See Our Article Receive The Eberhard F. Mammen Most Popular Article Award 2026
-
Mar 16, 2026, 19:03Limited Evidence for Anticoagulation Despite High VTE Risk in Sickle Cell Disease – RPTH
-
Mar 16, 2026, 18:59Bartosz Hudzik: Choosing The Right Anticoagulant for Acute Venous Thromboembolism
-
Mar 16, 2026, 18:54Michael Recht Appointed Chief Medical and Scientific Advisor to NBDF’s Pathway to Cures
-
Mar 16, 2026, 18:46David McIntosh: Moving Beyond Doubts and Ensuring the Safety of Plasma Donation
-
Mar 16, 2026, 18:42Ramy Abdelnaby: Exploring Advances in Antithrombotic Therapy for Noncardioembolic Ischemic Stroke
-
Mar 16, 2026, 18:27Christina (Tina) P: Help Advance Research and Support Patients with Antiphospholipid Syndrome
-
Mar 16, 2026, 18:20Ahmed Koriesh: Stroke Prevention in the New 2026 ACC/AHA Dyslipidemia Guideline
-
Mar 16, 2026, 18:13Nameer Ascandar: Outcomes After GI Bleeding in Patients with Rheumatoid Arthritis and AF on Long-Term Oral Anticoagulation